Stalicla

Genîve, Switzerland

STALICLA is a biotechnology company developing precision medicine treatments for patients with neurodevelopmental disorders.

$13.6M raised

Jan 2024

Series B

Top Investors

LIFTTSPRIM Global InvestmentsAA Sons

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Stalicla raised?

Stalicla has raised $13.6M in total funding. The most recent round was Series B. The last funding was announced in January 2024.

Who are Stalicla's investors?

Stalicla's investors include LIFTT, SPRIM Global Investments, AA Sons.

Where is Stalicla headquartered?

Stalicla is headquartered in Genîve, Switzerland.

What does Stalicla do?

STALICLA is a biotechnology company developing precision medicine treatments for patients with neurodevelopmental disorders.

What stage is Stalicla at?

Stalicla is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 16, 2024.

MLA

"Stalicla — Funding & Investors." VCBacked, January 16, 2024, https://www.vcbacked.co/company/stalicla. Accessed June 3, 2026.

APA

VCBacked. (2024). Stalicla — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/stalicla

Wikipedia (cite web)

{{cite web |title=Stalicla — Funding & Investors |url=https://www.vcbacked.co/company/stalicla |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 16, 2024.